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Inuit were long-believed to have lower CVD risk than non-indigenous populations. [1] [2] [3] However, re-evaluation of population studies indicates that ischemic heart disease rates are similar between
Inuit and non-Indigenous people. 4 Furthermore, ongoing Westernization in many Inuit communities has intensified their exposure to CVD risk factors such as smoking, calorie-dense processed foods, and a more comfortable but also sedentary lifestyle, all of which affect CVD risk and prevalence. [4] [5] [6] [7] [8] [9] [10] Among classical CVD risk factors, Inuit adults tend to have higher plasma concentrations of LDL cholesterol than non-indigenous populations.
11-15
The predominant monogenic cause of elevated LDL cholesterol concentration in most global populations is familial hypercholesterolemia (FH, Online Mendelian Inheritance in Man
[OMIM] 143890). 16 Heterozygous FH (HeFH) prevalence may be as high as 1:200 in certain
European populations, and it is a potent predisposition state for early CVD. [11] [12] [13] To date, DNA sequencing and biochemical studies have identified >1,600 rare loss-of-function mutations in the gene encoding the LDL receptor (LDLR), which can increase LDL cholesterol levels by 100% or more, and underlie >95% of cases of molecularly diagnosed FH. 16 But despite the relatively high levels of LDL cholesterol observed in some Inuit, the role of LDLR gene variation has not been systematically studied. [13] [14] [15] We thus investigated the LDLR locus in Inuit and tested for association of variants therein with plasma lipids. Through Sanger sequencing and targeted genotyping, we found two new LDLR variants common to five Inuit subgroups from across North America and Greenland: 1) p.G116S was both dysfunctional in vitro and associated with a relatively large increase in plasma LDL cholesterol levels; while 2) p.R730W had minimal dysfunction and impact on the lipid profile.
Methods
For the purposes of this study, we referred to all participants as "Inuit"; however, acknowledge ol concentration in n n n mo m m m delian In I I I h he h h i i ri it ta t t nce in in in in M Committee. The Greenland population study was ethically approved by the Commission for Scientific Research in Greenland. Participants gave their written consent after being informed about the study both orally and in writing.
The LDLR promoter region and exons were Sanger sequenced within a discovery subset Project database. However, p.G116S was previously reported in a single hypercholesterolemic subject of unspecified ethnic background ascertained in a lipid clinic in Denmark.
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LDLR p.G116S is robustly associated with higher plasma LDL cholesterol concentration
We stratified plasma lipoprotein profiles according to LDLR p.G116S or p.R730W genotype ( Table 2 ). In each sample, p.G116S carriers had significantly higher total, non-HDL, and LDL cholesterol concentrations compared to non-carriers (Supplemental Tables 1A and 1B ). In the overall sample p.G116S was associated with a ~0.54 mmol/L (20.9 mg/dL) increase in LDL cholesterol per copy (Table 3 ; P = 5.6 x 10 -49 ); mean plasma apolipoprotein (apo) B and non-HDL cholesterol concentrations were also proportionately higher per copy of p.G116S. In contrast, p.R730W was not significantly associated with LDL cholesterol overall (P = 0.13). In ), and tended to be higher still in p.G116S homozygotes compared to heterozygotes (P=0.058). In contrast, the relationship between p.R730W and plasma LDL cholesterol concentrations was not significant overall. Each copy of p.G116S was associated with increased risk of hypercholesterolemia, defined as a plasma LDL cholesterol >5.0 mmol/L, which Canadian dyslipidemia guidelines 23 suggest as the cutpoint for prescription of lipid-lowering treatment ( Figure 2 ; OR 3.02, 95% CI 2.34 -3.90, P = 1.7 x 10 -17 ). In contrast, p.R730W was not associated with increased risk of clinically actionable hypercholesterolemia.
LDLR p.G116S has a larger effect size on LDL cholesterol than the APOE E4 isoform
We compared the effect size of p.G116S to that of the APOE E4 isoform, a well-established ) and tended to ster r rol ol ol o co co conc nc nce e entr t tra a ations were also proporti ion on ona ately higher per co co copy of p.G116S. In R R R7 R 3 3 30 3 W was n not t t sig gn n ni n fi fica ca ca c ntly y y y asso ocia a ate ed wi w th h h L L LDL DL DL cho h holest ter r rol l l o o overal al al all l l l (P P P = 0 0 0. 0 1 1 13 1 ) 24, 25 In Inuit, APOE E4 allele frequencies ranged from 21% to 27% (Supplemental Table 2 ) and each copy of E4 increased LDL cholesterol by 0.18 mmol/L (7.0 mg/dL; P = 9.0 X 10 -11 ). Furthermore, the top LDL cholesterol-associated variants from genome-wide association (GWA) studies had effect sizes per allele ranging from 0.05 to 0.18 mmol/L. 26 Thus, LDLR p.G116S in Inuit is unique, with >3-fold larger effect on LDL cholesterol than any other common variant.
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LDLR p.G116S impairs LDLR ligand binding activity in vitro
Finally, we investigated the function of both variants in vitro, using cell-based models transfected with plasmid constructs encoding wild-type, p.G116S, or p.R730W LDLR variants.
Overall, p.G116S tended to show increased mean mature LDLR expression by 31%, while p.R730W had reduced mean mature LDLR expression by 63% relative to the wild-type LDLR constructs. In vitro LDL-binding assays adjusted for total LDLR expression linked p.G116S with a significant 61% reduction in LDL binding ability, while p.R730W had a non-significant 12% reduction in binding ability ( Figure 3 ).
The LDLR p.G116S variant in exon 4 resides within the ligand binding domain. 27 Of missense or nonsense mutations in LDLR that cause monogenic FH, ~ 20% reside within exon 4, which is considered to be a mutational hot-spot. 28 The pathogenic relevance of p.G116 in receptor function was supported by identification of the p.G116C variant in a Polish patient with hypercholesterolemia. 29 In contrast, p.R730W is within in exon 15, which encodes an attachment site for O-linked carbohydrate chains; this domain has no clear functional role. 27 Fewer than 1% of disease-causing LDLR mutations reside within exon 15. 28 Sequence conservation analysis suggested stronger evolutionary conservation at p.G116 compared to p.R730 (Supplemental on LDL receptor function (Supplemental Table 3 ). Our discovery of the association between p.G116S and LDL cholesterol concentration is of particular interest from a public health perspective, as Inuit communities may currently be at the tipping point of environment-related increased risk of CVD and metabolic disorders. In other populations, every 1 mmol/L increase in LDL cholesterol corresponds to a ~20% increase in CVD and ~15% increase in all-cause mortality. 31 Thus, the ~0.5 mmol/L increase in LDL cholesterol per p.G116S allele could potentially lead to ~10% and ~7.5% increased risk of CVD and all-cause mortality, respectively. Our analyses indicated that p.G116S carriers were at a ~3-fold increased risk of high LDL cholesterol (>5 mmol/L) which suggested that p.G116S carriers were also more likely to be candidates for pharmacologic intervention than non-carriers (OR 3.02, 95% CI 2.34 -3.90, p = 1.7 x 10 -17 ). Unfortunately, data on CVD end points were not g and th th th the e e e la la la larg rg rg rge e e e ef ef ef effe fe fe fect ct ct cts s s s systematically collected in the surveys that comprised this study, so the possible impact of p.G116S on metabolic and CVD risk among the Inuit cannot be directly inferred at this time. A link between this genetic variant and CVD risk would need to be formally evaluated, for instance using Mendelian randomization or another appropriate prospective study design. Furthermore, it would be of interest to detect possible interactions between lifestyle factors, other risk factors and the phenotypic impact of LDLR p.G116S. While baseline between-population differences in lipid profiles might be consistent with environmental effects (Table 1) , we have not systematically collected comprehensive diet and lifestyle data; while we would like to do this in the future, such an analysis is beyond the scope of the present report.
As with all association studies, a potential risk of population stratification artefacts exists.
However, there are several reasons why we believe that this is not a major issue here. First, we adjusted for geographic location in the association and correlation analyses for the combined Inuit cohort; the association of G116S with LDL-C was highly significant with this adjustment variable included. Second, while the minor allele of G116S varies by geographic region, the directionality of the association by genotype is the same, and is individually significant, in each of the 5 subpopulations for LDL-C, and the related traits of TC, non-HDL-C and apo B (see Supplemental Tables 1A and 1B) 
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SUPPLEMENTAL MATERIAL
Methods
Lipid measurements
Methods for lipid measurement in the individual health surveys were previously reported. [1] [2] [3] [4] Generally, participants fasted for either 12 hours or overnight prior to blood sample collection.
LDL cholesterol was estimated using the Friedewald equation in all samples, except for those from Alaska, in which LDL cholesterol was directly measured.
Bioinformatic analysis
LDLR variant effects on receptor function were assessed using multiple in silico prediction algorithms including PMUT, 5 PolyPhen, 6 MutPred, 7 and SIFT. 8 Algorithm scores were included where available. Evolutionary conservation of amino acid residues at LDLR p.G116 and p.R730
was assessed using the BLAST alignment tool, which aligns homologous regions from a range of species. 9 Previously reported FH mutations in LDLR were referenced from the Human Gene Mutation Database 10 and the Western Database of Lipid Variants. 11 Large-scale genome sequencing databases from the 1000 Genomes Project (1,092 sequenced genomes from a multiethnic cohort) 12 and National Heart, Lung, and Blood Institute Grand Opportunity (NHLBI GO)
Exome Sequencing Project (ESP) 13 Exome Variant Server (EVS; variants from exome sequencing from 2,203 African-American and 4,300 European-American samples, details at http://evs.gs.washington.edu/EVS/) were used to determine the frequencies of LDLR p.G116S
and p.R730W in non-Inuit populations. APOE E4 effect sizes were calculated in comparison to E3 carriers using linear regression adjusted for age, sex and BMI in Kivalliq (N=200), Greenland (N=1,096), Inuvialuit region (N=212), Nunavik (N=383), SW Alaska (N=1,203) and a combined cohort (N=3,094). APOE E4 frequencies were calculated from larger populations including APOE E2, E3 and E4 carriers. APOE isoforms were inferred using TaqMan SNP genotyping assays for SNPs rs429358 and rs7412 (Applied Biosystems; Foster City, CA). 
Supplemental
